Symbiotec Pharmalab Sets IPO Price Band at ₹938–₹988

INDORE / MUMBAI — Active pharmaceutical ingredients (API) manufacturer Symbiotec Pharmalab Limited has announced the schedule and price band for its maiden initial public offering (IPO), setting the price bracket at ₹938 to ₹988 per equity share.

According to official public filings submitted to stock exchanges, the IPO will open for public subscription on August 24, 2026, and close on August 27, 2026. Anchor investors participating in the book-building issue are scheduled to bid a business day prior on August 21, 2026.

Issue Structure, Utilization of Funds, and Book-Running Lead Managers

The public offering aggregates up to ₹2,180 crore, comprising a fresh issue of equity shares worth ₹150 crore alongside an Offer for Sale (OFS) of up to ₹2,030 crore by promoter entities and existing private equity investors, including India Business Excellence Fund-III and Rosewood Investments.

According to regulatory filings, red herring prospectus disclosures, and merchant banking announcements:

• Price Band: ₹938 to ₹988 per equity share (face value ₹2 per share).

• Bidding Timeline: Anchor investor bidding opens on August 21, 2026; the main public issue opens on August 24 and closes on August 27, 2026.

• Fund Utilization: Net proceeds from the fresh issue component will be deployed toward debt repayment, funding working capital requirements, and general corporate purposes.

• Syndicate Lead Managers: Avendus Capital, JM Financial, Motilal Oswal Investment Advisors, and Nomura Financial Advisory and Securities (India) are managing the public issue.

Official Sources Section

• Securities and Exchange Board of India (SEBI): Official public issue filings, red herring prospectuses, and regulatory observations.

• BSE India Corporate Filings: IPO schedule notifications and price band announcements for Symbiotec Pharmalab Limited (BSE: SYMI.NS).

• National Stock Exchange of India (NSE): Primary market issuance trackers and exchange compliance circulars.

Quote Section

According to statements released by corporate executives and merchant banking advisors regarding the public issue:

"The establishment of the price band marks a significant milestone in our corporate journey, allowing institutional and retail investors to participate in our next phase of global pharmaceutical growth."

Why It Matters

For pharmaceutical sector investors and institutional funds, Symbiotec Pharmalab's public offering provides exposure to a leading global producer of corticosteroid and steroidal-hormone APIs. Capital raised through the public issue will strengthen the company's balance sheet, optimize debt levels, and support research-driven expansion across regulated international markets.

Key Facts at a Glance

• Company Name: Symbiotec Pharmalab Limited.

• Price Band: ₹938 to ₹988 per equity share.

• IPO Dates: August 24 – August 27, 2026 (Anchor bidding: August 21, 2026).

• Issue Size: Approximately ₹2,180 crore (Fresh issue of ₹150 crore + OFS of ₹2,030 crore).

• Listing Destinations: Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

FAQ Section

What is the price band for the Symbiotec Pharmalab IPO? The price band has been fixed at ₹938 to ₹988 per equity share.

When does the IPO open and close for subscription? The public issue opens on August 24, 2026, and closes on August 27, 2026, with anchor bidding scheduled for August 21, 2026.

What is the total size of the initial public offering? The IPO aims to raise approximately ₹2,180 crore through a combination of a fresh issue and an offer for sale.

Where will Symbiotec Pharmalab shares be listed? Following the allotment process, the company's equity shares will be listed on both the BSE and NSE.

Source: SEBI, BSE India, NSE India, The Economic Times